View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 29, 2017

CytomX starts dosing in Phase I/II trial of CX-2009 to treat solid tumours

US-based biopharmaceutical firm CytomX Therapeutics has started dosing patients in a Phase I/II clinical trial (PROCLAIM CX-2009) of CX-2009 for the treatment of patients with select advanced solid tumours.

US-based biopharmaceutical firm CytomX Therapeutics has started dosing patients in a Phase I/II clinical trial (PROCLAIM CX-2009) of CX-2009 for the treatment of patients with select advanced solid tumours.

CX-2009 is a probody drug conjugate (PDC) being developed to target CD-166 antigen expressed in various types of tumours such as breast, endometrial and prostate cancers.

PDC targets the antigen particularly in the tumour microenvironment and delivers a tubulin-destabilising maytansine payload called DM4 to the cancer cells. 

The dose-finding Phase I/II trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of CX-2009 as a monotherapy. 

The trial will include subjects with several types of tumours such as non-small cell lung, breast, ovarian, endometrial, cholangiocarcinoma (bile duct cancer), head and neck and castration-resistant prostate cancers. 

"We could potentially treat a number of cancers for which few, if any, treatment options exist."

CytomX Therapeutics president and CEO Sean McCarthy said: "With CX-2009, we are leveraging the high levels of CD-166 on many types of cancer cells despite its presence on normal tissue.

"By targeting CD-166 and localising the activity of the CX-2009 probody therapeutic to the tumour, we could potentially treat a number of cancers for which few, if any, treatment options exist."

The Phase I/II trial is part of the firm’s international modular umbrella clinical trial programme called PROCLAIM designed for development of probody therapeutics.

In 2014, CytomX signed a licence agreement to develop PDCs using its antibody masking technology and tumour-selective protease substrates in conjunction with ImmunoGen’s potent antibody drug conjugate cell-killing agents and engineered linkers. 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU